Sankyo Announces Completion of Subject Registration for ORIENT Clinical Trial.
The ORIENT is a double-blinded study to examine the effectiveness of olmesartan medoxomil on patients with mild to moderate diabetic nephropathy. The study, which was launched in the second quarter of 2003 and ends in 2009, covers 400 patients in Japan and Hong Kong.
Currently, olmesartan medoxomil is an angiotensin II receptor blocker approved in 32 countries worldwide and marketed in Japan under the trade name of Olmetec.
Source: JCN http://www.japancorp.net
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Oct 15, 2005|
|Previous Article:||Medinet to Support University of Tokyo Hospital's 22nd Century Medical Center Project for Immune Cell Therapy.|
|Next Article:||Meiji Seika Kaisha, Solvay Seiyaku Obtain Additional Approval for Fluvoxamine Maleate.|